This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through June 1, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
J&J's Innovative Medicine Business in Q2: Here's What to Watch
by Kinjel Shah
JNJ's Q2 Innovative Medicine results face scrutiny as Stelara biosimilar pressure offsets growth from key blockbusters and newer therapies ahead of earnings.
AZNNegative Net Change JNJNegative Net Change AMGNNegative Net Change ABBVNegative Net Change
biotechs pharmaceuticals
Amgen or Biogen: Which Biotech Stock Appears Better Poised?
by Kinjel Shah
AMGN stands out compared to Biogen given its broader product portfolio, pipeline depth and steadier growth outlook despite patent and competition risks.
BIIBNegative Net Change NVONegative Net Change LLYPositive Net Change AMGNNegative Net Change
biotechs pharmaceuticals
AstraZeneca's Enhertu Wins EU Nod for HER2-Positive Solid Tumors (Revised)
by Zacks Equity Research
AZN's Enhertu wins its sixth EU indication with a tumor-agnostic approval. Datroway moves closer to a first-line TNBC EU nod following a positive CHMP opinion.
AZNNegative Net Change AMRNNegative Net Change LQDAPositive Net Change IMCRNegative Net Change
biotechs
Roche Gets FDA Priority Review for Enspryng in Thyroid Eye Disease
by Zacks Equity Research
Roche won FDA priority review for Enspryng in thyroid eye disease, with a decision date in October and phase III data backing the filing.
RHHBYPositive Net Change NVONegative Net Change LLYPositive Net Change NRIXPositive Net Change
biotechs medical pharmaceuticals
What Sparked the $43B Jump in AbbVie's Market Cap in the Past Week?
by Zacks Equity Research
ABBV surged nearly 11% in a week as acquisitions, new approvals and pipeline expansion strengthen confidence in its long-term growth strategy.
ABBVNegative Net Change REGNPositive Net Change SNYPositive Net Change
biotechs medical pharmaceuticals
EVMN Stock Tanks as Phase IIb Urticaria Study Misses Primary Goal
by Zacks Equity Research
Evommune shares fall after its phase IIb CSU study misses the primary endpoint, prompting the company to halt further development of EVO756 for the indication.
EVMNPositive Net Change LQDAPositive Net Change KNSAPositive Net Change IMCRNegative Net Change
biotechs
CRMD's Growth Story Expands Beyond DefenCath Into New Trends
by Ahan Chakraborty
CorMedix broadens beyond DefenCath with Melinta assets, Rezzayo potential and cost synergies as reimbursement changes test long-term earnings durability.
CRMDNegative Net Change PFEPositive Net Change BAXPositive Net Change
biotechnology biotechs medical pharmaceuticals
CRMD Stock Outlook as DefenCath and Rezzayo Expand Growth Path
by Ahan Chakraborty
CorMedix is shifting from a single-product launch story as DefenCath drives revenue and Rezzayo adds long-term potential despite reimbursement headwinds.
CRMDNegative Net Change PFEPositive Net Change AMPHPositive Net Change
biotechnology biotechs medical pharmaceuticals
Is CRMD Stock a Buy Now After Strong Growth and New Risks?
by Ahan Chakraborty
CorMedix posted surging DefenCath-led revenue and stronger profitability, but reimbursement changes and execution risks could shape the stock's next phase.
CRMDNegative Net Change PFEPositive Net Change AMPHPositive Net Change
biotechnology biotechs medical pharmaceuticals
Can Eli Lilly's New Drugs Fuel Growth Beyond Its GLP-1 Blockbusters?
by Ahan Chakraborty
LLY is expanding its revenue base beyond Mounjaro and Zepbound with new launches and label expansions that can strengthen long-term growth.
LLYPositive Net Change NVONegative Net Change VKTXPositive Net Change GPCRPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals